about
NF-kappaB induced by IL-1beta inhibits elastin transcription and myofibroblast phenotypeHypoxia suppresses elastin repair by rat lung fibroblastsTracheobronchial amyloidosis. The Boston University experience from 1984 to 1999.Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis.Guideline of transthyretin-related hereditary amyloidosis for clinicians.Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patientsPleural effusions in systemic amyloidosis.Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients.High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center.Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure.Diaphragm paralysis in primary systemic amyloidosis.Artificial neural network modelling of ATTR amyloidosis: is now the time?Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience.Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis.Once AL amyloidosis: not always AL amyloidosisRegression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosisMacroglossia – not always AL amyloidosisThe diflunisal trial: update on study drug tolerance and disease progressionHigh-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year StudyCold-induced bronchoconstriction: role of cutaneous reflexes vs. direct airway effectsRegulation of type I collagen production by insulin and transforming growth factor-beta in human lung fibroblastsRetinoic acid-induced inhibition of type I collagen gene expression by human lung fibroblastsRegulation of lysyl oxidase expression in lung fibroblasts by transforming growth factor-beta 1 and prostaglandin E2Cardiac amyloidosis: evolving approach to diagnosis and managementQuality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisA library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeuticsHereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial
P50
Q28203494-C5E8C902-2410-4745-B56E-B6A6E830E314Q28572947-920828A7-0999-4C91-9EE3-4DE88BE799D2Q30859726-983DD061-FE4E-4831-9418-68612C8A7D19Q31075899-2031C7E2-957D-4B8B-BF5A-B028F3071ACDQ33288696-D9118440-295F-4A5B-A0ED-2A48A71B73F0Q33771326-B03DA2F5-D776-44D4-8B22-E2D9A9A61F80Q34328734-92FDF5B3-0A31-4096-BB52-E8FDF2137505Q35485742-7CA13B7A-0CE9-44EA-A019-C3184336B887Q36146702-DCE00565-6C3E-4E06-B788-C413AC1D1F34Q43592586-EB7E6634-7CC9-4A8D-9C64-EB785876AB38Q45871914-3B0B04E9-B649-495C-A0A9-F75050D88A4BQ46334504-95256E2F-FCAF-4A57-94F1-58D75E1F1964Q46926863-4B5F99C3-3C2C-4188-B526-63459CC05349Q47719175-149FB445-5A81-4B24-8162-C222FC154528Q48107770-1F04A87B-5636-4273-B126-F3B760C8F1F1Q48123471-5CBA04E0-94C1-4072-8E24-DF4FCDCDE4A9Q50051766-96CFBAE7-E23A-42C4-B326-6DF25EFE0828Q51940628-89AA83AA-96BB-4BDD-B326-7624E998C5FFQ52551788-87562C41-91A6-414D-BD02-D769AB3FA007Q58124969-FD59BA66-03A2-40E4-8F7B-4123A4C7DAFCQ58124973-913CE05F-70FB-4C82-B409-3F576488BFEBQ58294866-CFE7CCD9-0592-41CA-8FCE-19BA4D4E211BQ58305010-535F510C-9EE5-4EEF-9731-992F668D163BQ63413690-9305231F-91AC-4E86-B7FD-6E145AAEFC18Q69399375-D8A79EB2-8A95-493C-BBB2-03F4495DEA3EQ71603671-F0C4EB9A-97F2-43B6-94ED-8B7D0AC03781Q72697115-EE3A0103-6ABE-4A01-909A-6B126A407213Q72769876-83E720D5-8443-489E-80E0-81CC42A3F511Q85076497-3941D496-D99A-4E59-AAD1-D90F2E0D5315Q90048672-DAB56B0A-4F54-4495-A99D-29C64B808681Q90389817-EB45FFE7-3844-469B-8EB4-1BDA645647B7Q91250702-FF62F215-8CF4-44A4-9FBD-CBBCBDE1FF2A
P50
description
researcher ORCID ID = 0000-0002-1768-2373
@en
wetenschapper
@nl
name
John L Berk
@ast
John L Berk
@en
John L Berk
@es
John L Berk
@nl
type
label
John L Berk
@ast
John L Berk
@en
John L Berk
@es
John L Berk
@nl
prefLabel
John L Berk
@ast
John L Berk
@en
John L Berk
@es
John L Berk
@nl
P31
P496
0000-0002-1768-2373